Overview

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

Status:
Terminated
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the long-term safety and efficacy of idebenone in patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study.
Phase:
Phase 3
Details
Lead Sponsor:
Santhera Pharmaceuticals
Treatments:
Idebenone
Ubiquinone